The drug, a grape-flavored solution called maralixibat, is approved for children age 1 and older. Foster City, California-based Mirum will market its new product under the name “Livmarli.” Alagille ...
FOSTER CITY, Calif. & YONGIN, South Korea--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and GC Pharma (KRX:006280) today announced that they have entered into an exclusive licensing ...
Mirum Pharmaceuticals Inc. plans to “move rapidly toward regulatory filings” to expand use of IBAT inhibitor Livmarli (maralixibat) into progressive familial intrahepatic cholestasis (PFIC), President ...
Like two crafty boxers, Albireo and Mirum Pharmaceuticals are bobbing and weaving, answering punches with counterpunches, in their battle to treat a trio of pediatric liver diseases with their ...
Mirum Pharmaceuticals is at an inflection point. The company's sales are growing fast, led by the success of Livmarli. Mirum has multiple potential catalysts on the way in 2026. In several important ...
Although progressive familial intrahepatic cholestasis (PFIC) tends to draw more hoopla in the race, and Mirum Pharmaceuticals Inc. looks due to beat Albireo Pharma Inc. to market in Alagille syndrome ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical ...
Mirum Pharmaceuticals was profitable in the third quarter. However, top-line growth for the midcap biotech will slow this year. A recent acquisition could also negatively affect the bottom line.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results